Startup diligence,
written by AI.

Opentrons Labworks

Opentrons has real product, customer, and investor relevance, but the public record is still too thin to justify paying the 2021 unicorn price with confidence.

Valuation

$1.8B

HubX

Real consumer-AI scale story with strong operating signals, but not enough public denominators to justify a buy recommendation at the disclosed unicorn price.

Valuation

$1.2B

VNLIFE

VNLIFE is a real scaled Vietnamese payments platform with durable strategic relevance, but thin public economics and only an indicative >US$1B secondary valuation anchor support a RESEARCH MORE recommendation rather than an aggressive buy.

Tarana Wireless

Tarana has credible deep-tech broadband infrastructure and real operator adoption, but the public disclosure package still lags the valuation levels implied by late-stage private-market screens.

Valuation

$2B

Astronomer

Astronomer appears to be a real category leader in enterprise Airflow and DataOps, but the public record supports a track decision rather than a clean buy because valuation, concentration, and margin transparency lag the strength of the product and customer evidence.

Valuation

$775M

Growth

55%

NRR

120%

Pragmatik Labs

Exceptional founder pedigree + massive market; valuation is a pre-product conviction bet with high execution risk and severe evidence gaps at every chapter of diligence.

Valuation

$2B

WeLion New Energy

WeLion has real commercialization proof, rare Chinese semi-solid battery credibility, and a plausible IPO path, but the current RMB 18.5-20.0bn valuation narrative still runs ahead of public evidence on revenue, margins, customer concentration, and manufacturing quality, making Track the most defensible call at low confidence.

Valuation

$2.7B

Hello TransTech

Hello looks strategically important and plausibly valuable, but the current ~$6 billion mark still appears fair-to-full until private financials, cap-table terms, and remediation quality become materially clearer.

Valuation

$6B

MediTrust Health

MediTrust Health is a real scaled China healthcare-payments infrastructure asset with strong insurer and pharma reach, but current public evidence still points to high execution and pricing risk, making the last private valuation look stretched unless investors get better disclosure, a discounted entry, or explicit downside protection.

Valuation

$1.6B

Revenue run-rate

$312M

Growth

62%

Yuanxin Technology

Yuanxin has real scale and category leadership, but the RMB 19.5B pre-IPO mark looks stretched relative to its low margins, slower growth, and unresolved IPO/dilution risk.

Valuation

$2.7B

Growth

1.7%

New Ruipeng Pet Healthcare Group

New Ruipeng is a strategically important scaled pet-healthcare asset, but the current Hurun-like valuation reference still looks expensive versus the last disclosed revenue base and the available public comp set.

Revenue run-rate

$832.2M

Growth

20.1%

Cleo

Cleo looks like a real scaled AI-first consumer-finance company, but incomplete price and risk disclosure keep the current call at track rather than buy.

Valuation

$1B

Revenue run-rate

$186M

ARR

$280M

Growth

106%